Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vibrating mesh nebuliser ease breathing for COPD patients on ventilation?

NCT ID NCT06884228

Disease control Sponsor: Guy's and St Thomas' NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether a vibrating mesh nebuliser delivers bronchodilator medication more effectively than a standard jet nebuliser in people with COPD who use non-invasive ventilation at home. Researchers will measure breathing muscle activity, lung function, and breathlessness after each type of nebuliser. The goal is to see if the vibrating mesh device improves drug delivery and reduces the work of breathing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vibrating mesh nebulisation device
What this could lead to
If vibrating mesh nebulisation proves more effective, it could improve drug delivery and breathing comfort for COPD patients using non-invasive ventilation.
What could go wrong
This is a very small, early-stage study with only 12 participants, so results may not apply broadly. The intervention is a device, not a new drug, so the potential impact is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with COPD receiving home non-invasive ventilation for chronic respiratory failure under the Lane Fox Respiratory Service at Guy's and St Thomas' NHS Foundation Trust * Tolerating home non-invasive ventilation for at least 4 hours/24 hours * Aged 18-80 years old * Able to communicate symptom burden to the research team * Able to give informed consent for participation in the study * Clinical stability, with no acute exacerbations of COPD for 2 weeks prior to enrolment Exclusion Criteria: * Severe, non-respiratory organ dysfunction including, but not limited to: * Congestive cardiac failure * Significant cardiovascular disease * End-stage malignancy * End-stage renal failure * Acute pulmonary pathology requiring emergency treatment including, but not limited to: * Pneumonia * Pneumothorax * Pulmonary embolism * Severe cognitive impairment * Psychosocial factors that would preclude completion of the study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD, chronic obstructive pulmonary disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD, chronic obstructive pulmonary disease Non invasive ventilation

Contacts and locations

Locations

  • Lane Fox Unit, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust

    London, SE1 7EH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.